Department of Surgery (A), Medical Faculty, Heinrich-Heine-University and University Hospital, Duesseldorf, Germany.
Institute of Pathology, Medical Faculty, Heinrich-Heine-University and University Hospital, Duesseldorf, Germany.
Surgery. 2021 Dec;170(6):1807-1814. doi: 10.1016/j.surg.2021.06.045. Epub 2021 Aug 13.
Para-aortic lymph nodes in the ductal adenocarcinoma of the pancreatic head are regarded as distant metastases. Chemotherapy is considered the only treatment option if para-aortic lymph nodes metastases are detected preoperatively or intraoperatively. The role of standardized para-aortic lymph node lymphadenectomy during pancreaticoduodenectomy remains controversial. The aim of this study was to evaluate complication profiles and survival.
All cases of ductal adenocarcinoma of the pancreatic head were evaluated from a prospectively maintained database (n = 289). Para-aortic lymph node lymphadenectomy was routinely performed in all patients with suspected ductal adenocarcinoma of the pancreatic head. Subgroup analysis was performed between patients with histologically positive (+) and negative (-) para-aortic lymph nodes. Patients receiving pancreaticoduodenectomy without para-aortic lymph node lymphadenectomy for other causes served as a control group.
A total of 192 patients received para-aortic lymph node lymphadenectomy, of which 41 were positive for para-aortic lymph node metastases. In 97 patients with ductal adenocarcinoma of the pancreatic head, no para-aortic lymph node lymphadenectomy was performed owing to postoperative pancreatic ductal adenocarcinoma diagnosis. Clinicopathologic data were homogenously distributed. Hospital stay and postoperative morbidity demonstrated no significant difference between the 3 subgroups. The median overall survival of 19.63 months (95% confidence interval: 14.57-24.79 months) in para-aortic lymph node- patients was not statistically different when compared with the median overall survival of 18.22 months (95% confidence interval: 12.68-23.75 months) in para-aortic lymph node + patients (log-rank test P = .223). Preoperative computed tomography was a poor predictor for para-aortic lymph node status (sensitivity = 10.3%, specificity = 97.8%).
This study represents the largest cohort receiving routine para-aortic lymph node lymphadenectomy. Extended lymphadenectomy can be performed safely and, although disease-free survival of para-aortic lymph node+ patients was significantly shorter, overall survival and postrelapse survival were on par with that of para-aortic lymph node- patients. Preoperative computed tomography indicating para-aortic lymph node metastasis should not preclude curative resection.
在胰头导管腺癌中,腹主动脉旁淋巴结被视为远处转移。如果术前或术中发现腹主动脉旁淋巴结转移,则认为化疗是唯一的治疗选择。在胰十二指肠切除术中,标准化的腹主动脉旁淋巴结清扫术的作用仍存在争议。本研究旨在评估并发症谱和生存率。
从一个前瞻性维护的数据库中评估所有胰头导管腺癌病例(n=289)。所有疑似胰头导管腺癌患者均常规行腹主动脉旁淋巴结清扫术。对病理检查阳性(+)和阴性(-)腹主动脉旁淋巴结的患者进行亚组分析。因其他原因未行腹主动脉旁淋巴结清扫术而行胰十二指肠切除术的患者作为对照组。
共有 192 例患者接受了腹主动脉旁淋巴结清扫术,其中 41 例腹主动脉旁淋巴结转移阳性。在 97 例胰头导管腺癌患者中,由于术后诊断为胰腺导管腺癌,未行腹主动脉旁淋巴结清扫术。临床病理数据分布均匀。3 个亚组之间的住院时间和术后发病率无显著差异。行腹主动脉旁淋巴结清扫术的患者中位总生存期为 19.63 个月(95%置信区间:14.57-24.79 个月),与行腹主动脉旁淋巴结清扫术的患者中位总生存期 18.22 个月(95%置信区间:12.68-23.75 个月)相比,差异无统计学意义(对数秩检验 P=0.223)。术前计算机断层扫描对腹主动脉旁淋巴结状态的预测效果较差(敏感性 10.3%,特异性 97.8%)。
本研究是接受常规腹主动脉旁淋巴结清扫术的最大队列。扩大淋巴结清扫术可以安全进行,尽管腹主动脉旁淋巴结阳性患者的无病生存期明显缩短,但总生存期和复发后生存期与腹主动脉旁淋巴结阴性患者相当。术前计算机断层扫描提示腹主动脉旁淋巴结转移不应排除根治性切除。